How Popular Weight-Loss Medications Are Complicating DUI Prosecutions
Every legal assistant, paralegal, and trial attorney has seen the routine narrative unfold: a client gets pulled over, performs a standard field sobriety test, and by the time they reach the police precinct one or two hours later, a breath test or legal blood draw for blood alcohol concentration (BAC) is collected. The prosecution routinely presents this chemical test as airtight, objective truth, bringing in state toxicologists to "back-calculate" impairment to the precise minute the vehicle was in motion. However, what if the standard forensic math relies on assumptions that are no longer completely valid? Across the legal landscape, tens of millions of drivers are taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—blockbuster weight-loss and diabetes treatments such as semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda). While these medications transform glycemic control and metabolic health, they trigger significant physiological disruptions that complicate standard forensic toxicology. For defense counsel in a DUI/DWI case, recognizing whether a defendant is taking a GLP-1 medication can expose flaws in the state's case. Engaging a specialized forensic expert witness can make the difference between an unjust conviction and a successful defense.
Standard courtroom toxicology depends heavily on a single foundational assumption: that an orally-ingested drink absorbs quickly, cleanly, and predictably, reaching peak concentration within a narrow 30-to-90-minute window and virtually never exceeding two hours post-consumption. Under normal human physiology, the stomach absorbs only a minor fraction of alcohol; roughly 80% or more passes through the pyloric sphincter into the duodenum and jejunum (the proximal small intestine), where rapid systemic absorption takes place. However, GLP-1 RAs disrupt this mechanism. These medications activate enteric neuronal pathways and stimulate what gastroenterologists term the "ileal brake" reflex, deliberately paralyzing and decelerating upper gastrointestinal motility. A meta-analysis published in the American Journal of Gastroenterology revealed that GLP-1 RAs extend solid-phase gastric half-emptying time (T1/2) by an average of 36 minutes compared to unmedicated controls (Hiramoto et al., 2024). Additionally, clinical trials by Maselli et al. (2022) revealed that up to 57% of patients developed measurable delays in gastric emptying, with roughly half maintaining those delays across four months of continuous therapy. Assessments highlighted by Parkman et al. (2024) note that up to 75% of individuals with previously normal gastric motility exhibit measurable slowing after initiating GLP-1 therapy (Parkman et al., 2024).
When gastric motility slows down, ingested ethanol remains sequestered in the gastric lumen alongside retained solid nutrients. Instead of entering the bloodstream in a rapid, unimodal wave, the alcohol slowly trickles into the small intestine over hours. A preliminary study by Quddos et al. (2025) confirmed that individuals taking GLP-1 agonists experience a marked lag in the rise of breath alcohol concentration compared to unmedicated controls. As such, when ethanol is physically trapped inside the stomach, it cannot cross into systemic circulation to cause cerebral intoxication.
Consider a client who consumed a drink an hour before getting behind the wheel. Under standard conditions, police would assume the alcohol was already fully absorbed. However, with a GLP-1 RA acting as a pharmacological barrier, the beverage remains sequestered within the stomach. At roadside, the client may show little or no actual cognitive or motor impairment because circulating blood levels remain low. Nonetheless, through the transport of the client to a booking station or hospital one to two hours later, that trapped reservoir of stomach alcohol finally meters through the pylorus into the small intestine. Circulating blood levels spike rapidly, registering an elevated BAC reading that is not representative of the true concentration at the time of alleged offense.
Toxicologists rely on "retrograde extrapolation"—a backward calculation based on standard mathematical curves—to claim that if the driver blew over the limit at the station, they must have been at an even higher concentration while driving hours earlier. However, this requires one absolute, non-negotiable prerequisite: The individual must have been in the post-absorptive (terminal elimination) phase at the time of driving. If the defendant was still in an extended rising phase or experiencing a biphasic absorption profile due to GLP-1 therapy, back-calculating yields a scientifically invalid, inflated overestimation of the BAC at the time of vehicle operation. Forensic reviews, such as those analyzing retrograde extrapolation reports from the Minnesota Bureau of Criminal Apprehension (BCA), reveal that state crime labs routinely fail to account for GLP-1 medications or gastrointestinal motility disorders when generating these estimates (Olson, 2025). An experienced expert witness can present this data to address the validity and representativeness of the prosecution's timeline.
Are there other physiological effects of GLP-1 RAs that are worth considering? The disruptions do not stop with delayed stomach emptying. GLP-1 receptor agonist therapy alters metabolic chemistry and motor balance in ways that distort forensic evidence. For example, metabolic ketosis can have an effect with Breathalyzers. Rapid weight reduction and severe caloric deficits shift cellular metabolism toward fatty acid oxidation, which can generate elevated levels of endogenous breath acetone (a ketone body) and its metabolite, isopropanol. These volatile compounds can cross-react with infrared and electrochemical fuel-cell sensors on evidential breath-testing devices, resulting in false positives or artificially inflated breath alcohol results. Additionally, delayed gastric emptying frequently triggers severe acid reflux and regurgitation. Regurgitated fluids carry residual stomach alcohol upward into the oral cavity, creating mouth-alcohol contamination that inflates evidential breath readings. Also, emerging preclinical research indicates that semaglutide, arguably the most prominent GLP-1 RA, suppresses key hepatic enzymes responsible for alcohol clearance, lowering individual clearance rates below textbook averages (typically 0.015 to 0.020 g/dL/h) (Jerlhag, 2026). Lastly, central and autonomic actions of GLP-1 RAs regularly trigger dizziness, vertigo, nausea, and lethargy. On video, a client struggling with medication-induced nausea or vestibular instability can display clues on Standardized Field Sobriety Tests (SFSTs)—such as unsteady balance on the Walk and Turn or lack of smooth pursuit on Horizontal Gaze Nystagmus (HGN)—which arresting officers misinterpret as signs of intoxication.
The take-home message is that when a client's DUI charge involves an elevated BAC, it can be immensely valuable to examine the client’s medical history. Are they taking weekly injections of Wegovy, Ozempic, Mounjaro, or daily doses of liraglutide? Did they take their dose recently, experience gastrointestinal symptoms, or eat a solid meal shortly before their arrest? Translating these complex pharmacokinetic processes into admissible, compelling courtroom evidence requires specialized expert testimony. Qualified expert witnesses can challenge the prosecution's state lab assumptions under Daubert or Frye standards, demonstrate the post-absorptive fallacy, and cross-examine state toxicologists on the assumptions made in their calculations.
References
Hiramoto, B., McCarty, T. R., Lodhia, N. A., Jenkins, A., Elnaiem, A., Muftah, M., Flanagan, R., & Chan, W. W. (2024). Quantified metrics of gastric emptying delay by glucagon-like peptide-1 agonists: A systematic review and meta-analysis with insights for periprocedural management. The American Journal of Gastroenterology, 119(6), 1126–1140. https://doi.org/10.14309/ajg.0000000000002820
Jerlhag, E. (2026). GLP-1 and alcohol-related behaviors: Insights from preclinical studies. Biological Psychiatry, 99(2), 112–124. https://doi.org/10.1016/j.biopsych.2025.08.012
Maselli, D., Atieh, J., Clark, M. M., Chedid, V., Vial, L. C., Breen-Lyles, M., Harmsen, W. S., Burton, D. D., Busciglio, I., & Camilleri, M. (2022). Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial. Obesity, 30(8), 1608–1620. https://doi.org/10.1002/oby.23481
Olson, A. (2025). Extended absorption, implications: Rethinking alcohol pharmacokinetics in forensic calculations. Medico-Legal Journal, 94(1), 24–27. https://doi.org/10.1177/00258172251382701
Parkman, H. P., Rim, D. S., Anolik, J. R., Dadparvar, S., & Maurer, A. H. (2024). Glucagonlike peptide-1 receptor agonists: The good, the bad, and the ugly—Benefits for glucose control and weight loss with side effects of delaying gastric emptying. Journal of Nuclear Medicine Technology, 52(1), 3–7. https://doi.org/10.2967/jnmt.123.266800
Quddos, F., et al. (2025). [Study on GLP-1 receptor agonists and delayed breath alcohol concentration kinetics]. (Preliminary study).